Additional file 1: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Table S1. Baseline clinical characteristics of patients with rheumatoid arthritis. Table S2. Mean and standard deviation (SD) of synovial biomarker expression. Table S3. Mean and standard deviation (SD) of serum metabolites detected by 1H-NMR (ÎźM). Reference values are from the Human Metabolome Database (HMDB) and were collected via NMR, unless otherwise noted. 1GC/MS; 2HPLC; 3HPLC-fluoroescence; 4ion-exchange chromatography; 5DFI/MS/MS 6unknown. ND, no data available. Metabolites that were upregulated by at least 20% compared to reference values are in green. Metabolites that were downregulated by more than 20% compared to reference values are in red. (DOCX 26 kb

Additional file 4: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S3. Correlation between serum metabolites and synovial CD19, CD79A, and IgGHC. (TIFF 14826 kb

Additional file 6: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S5. Correlation between serum metabolites and synovial MMP1, MMP3, and IL-6. (TIFF 14826 kb

Additional file 8: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S7. Correlation between serum cytokines and synovial cytokines and serum metabolites. (TIFF 14826 kb

Additional file 3: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S2. Pathway analysis of polar compounds by MetaboAnalyst. (TIFF 14826 kb

Additional file 2: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S1. Correlation between synovial markers and serum metabolites. (TIFF 14826 kb

Additional file 5: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S4. Correlation between serum metabolites and synovial APRIL, CD138, SDF1, IgKappa, and IgMHC. (TIFF 14826 kb

Additional file 1 of Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes

Additional file 1: Supplementary Figure 1. PLS-DA and RF analysis of serum metabolomic profiling at time zero. PLS-DA and RF analysis at time zero resulted in a good discrimination and prediction of the samples per BMI (A), but not per number of flares (B), or hyperuricemia (HU) > 8 mg/dL (C), or presence of tophi (D). Supplementary Figure 2. XOI-based ULT effects on serum metabolomic profiling. (A) PCA examining samples at time zero as well as at 12 and 24 weeks ULT titration to target. (B) Hierarchical clustering analysis at three time points. (C) Random Forest (RF) analysis using metabolite data derived from sera collected at baseline, or at 12 and 24 weeks ULT titration to target. (D) Top metabolites generated by RF analysis resulted in predictive accuracy of 52% (compared to 33% expected by random chance alone). Supplementary Figure 3. Validation of XOI-based ULT effects on xanthine and purine metabolism by serum metabolomic profiling. (A) Levels of ULT drugs included in the treatment and in metabolites related to purine and xanthine metabolism were significantly elevated in samples collected at 12- and 24-weeks treatment. Green: indicates significant difference (p≤0.05) between the groups shown, metabolite ratio of < 1.00. Light Green: narrowly missed statistical cutoff for significance 0.0

Additional file 3 of Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes

Additional file 3. Supplementary methods

Additional file 2 of Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes

Additional file 2: Supplementary Table 1. Included the 1105 compounds of known identity from the Metabolon platform. Supplementary Table 2. Relative levels of fatty acids identified in the UCSD cohort. Supplementary Table 3. Fatty acids identified in the Omaha cohort. Concentrations are reported in pmol/mL of plasma